Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

STATUS

Recruiting
End date

Dec 31, 2025
participants needed

400
sponsor

Seattle Genetics, Inc.

Send

Updated on 19 February 2024

See if I qualify

ct scan

measurable disease

formalin-fixed paraffin-embedded

stem cell transplantation

rituximab

lymphoma

positron emission tomography

lenalidomide

systemic therapy

b-cell lymphoma

stem cell mobilization

brentuximab vedotin

ffpe

avid

brentuximab

diffuse large b-cell lymphoma

large b-cell lymphoma

Summary

This study is being done to see if adding brentuximab vedotin helps two drugs work better to treat patients with diffuse large B-cell lymphoma (DLBCL). Participants in this study will have DLBCL that has come back or not gotten better with treatment.

Patients will be randomly assigned to get either brentuximab vedotin or placebo. The placebo will look like brentuximab vedotin, but has no medicine in it. Since the study is "blinded," patients and their doctors will not know whether a patient gets brentuximab vedotin or placebo. All patients in the study will get rituximab and lenalidomide. These are drugs that can be used to treat DLBCL.

Details

Condition	Diffuse Large B-Cell Lymphoma
Age	18years - 100years
Treatment	Placebo, Rituximab, Lenalidomide, Brentuximab vedotin
Clinical Study Identifier	NCT04404283
Sponsor	Seattle Genetics, Inc.
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	b'Participants with relapsed or refractory diffuse and transformed large B-cell lymphoma'
	b'(R/R DLBCL). DLBCL and cell of origin (GCB versus non-GCB) will be histologically'
	b'determined by local pathology assessment for the purposes of study eligibility and'
	b'tratification.'
	b'Participants must have R/R disease following 2 or more lines of prior systemic'
	b'therapy.'
	b'Participants must be HSCT or CAR-T ineligible according to the investigator and must'
	b'meet at least one of the following criteria:'
	b'One or more co-morbidities, including cardiac, pulmonary, renal or hepatic'
	b'dysfunction that in the opinion of the Investigator make the subject medically'
	b'unfit to received HSCT or CAR-T therapy'
	b'Active disease following induction and salvage chemotherapy'
	b'Inadequate stem cell mobilization (for HSCT)'
	b'Relapse following prior HSCT or CAR-T'
	b'Unable to receive CAR-T therapy due to financial, geographic, or insurance issues'
	b'Participants will need to have a formalin-fixed paraffin-embedded tumor tissue'
	b'(obtained \\u22644 weeks before Day 1) submitted to the central pathology lab.'
	b'An Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2'
	b'Participants must have fluorodeoxyglucose (FDG)-avid disease by positron emission'
	b'tomography (PET) and bidimensional measurable disease of at least 1.5 cm by computed'
	b'tomography (CT), as assessed by the site radiologist within 28 days of Day 1.'
	b'Participants must be registered into the mandatory lenalidomide REMS\\xae program and be'
	b'willing to comply with its requirements. Per standard lenalidomide REMS\\xae program'
	b'requirements, all physicians who prescribe lenalidomide for research subjects enrolled'
	b'into this trial, must be registered in, and must comply with, all requirements of the'
	b'lenalidomide REMS\\xae program.'
Exclusion Criteria
	b'History of another malignancy within 2 years before the first dose of study drug or'
	b'any evidence of residual disease from a previously diagnosed malignancy'
	b'History of progressive multifocal leukoencephalopathy (PML)'
	b'Active cerebral/meningeal disease related to the underlying malignancy. Subjects with'
	b'a history of cerebral/meningeal disease related to the underlying malignancy are'
	b'allowed if prior CNS disease has been effectively treated and without progression for'
	b'at least 3 months.'
	b'Any uncontrolled Grade 3 or higher (per NCI CTCAE version 5.0) viral, bacterial, or'
	b'fungal infection within 2 weeks prior to the first dose of study drug. Routine'
	b'antimicrobial prophylaxis is permitted'
	b'Chemotherapy, radiotherapy, biologics, and/or other antitumor treatment with'
	b'immunotherapy that is not completed 3 weeks prior to first dose of study drug, unless'
	b'underlying disease has progressed on treatment'
	b'Participants who are breastfeeding'
	b'Known hypersensitivity to any study drug or excipient contained in the drug'
	b'formulation of the study drugs'
	b'Known to be positive for hepatitis B by surface antigen expression. Known to be'
	b'positive for hepatitis C infection (positive by polymerase chain reaction [PCR] or on'
	b'antiviral therapy for hepatitis C within the last 6 months). Participants who have'
	b'been treated for hepatitis C infection are permitted if they have documented sustained'
	b'virologic response of 12 weeks.'
	b'Participants with previous allogeneic HSCT if they meet either of the following'
	b'criteria:'
	b'<100 days from HSCT'
	b'Active acute or chronic graft-versus-host disease (GVHD) or receiving'
	b'immunosuppressive therapy as treatment for or prophylaxis against GVHD'
	b'Previous treatment with brentuximab vedotin or lenalidomide'
	b'Current therapy with immunosuppressive medications (including steroids), other'
	b'ystemic anti-neoplastic, or investigational agents'
	b'a) Prednisone (or equivalent) \\u226410 mg/day may be used for non-lymphomatous purposes'
	b'Documented history of a cerebral vascular event (stroke or transient ischemic attack),'
	b'unstable angina, myocardial infarction, or cardiac symptoms consistent with New York'
	b'Heart Association (NYHA) Class III-IV within 6 months prior to the first dose of study'
	b'drugs'
	b'Congestive heart failure, Class III or IV, by the NYHA criteria'
	b'Grade 2 or higher peripheral sensory or motor neuropathy at baseline'

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

I am at least 18 years old.

By sending a message, I agree to share my information with the study team for the selected site and consent to receive emails and text messages for trial updates, notifications, and related communication. TrialX values your privacy; your information will be handled in accordance with our Privacy Policy

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

ct scan

measurable disease

formalin-fixed paraffin-embedded

stem cell transplantation

rituximab

lymphoma

positron emission tomography

lenalidomide

systemic therapy

b-cell lymphoma

stem cell mobilization

diffuse large b-cell lymphoma

large b-cell lymphoma

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL